Focal cortical dysplasia type IIb (FCD IIb) and tuberous sclerosis complex (TSC) are well-recognized causes of chronic intractable epilepsy in children. Accumulating evidence suggests that activation of the microglia/macrophage and concomitant inflammatory response in FCD IIb and TSC may contribute to the initiation and recurrence of seizures. The membrane glycoproteins CD47 and CD200, which are highly expressed in neurons and other cells, mediate inhibitory signals through their receptors, signal regulatory protein α (SIRP-α) and CD200R, respectively, in microglia/macrophages. We investigate the levels and expression pattern of CD47/SIRP-α and CD200/CD200R in surgically resected brain tissues from patients with FCD IIb and TSC, and the potential effect of soluble human CD47 Fc and CD200 Fc on the inhibition of several proinflammatory cytokines associated with FCD IIb and TSC in living epileptogenic brain slices in vitro. The level of interleukin-4 (IL-4), a modulator of CD200, was also investigated. Twelve FCD IIb (range 1.8–9.5 years), 13 TSC (range 1.5–10 years) patients, and 6 control cases (range 1.5–11 years) were enrolled. The levels of CD47/SIRP-α and CD200/CD200R were assessed by quantitative real-time polymerase chain reaction and western blot. The expression pattern of CD47/SIRP-α and CD200/CD200R was investigated by immunohistochemical analysis, and the cytokine concentrations were measured by enzyme-linked immune-sorbent assays. Both the messenger RNA and protein levels of CD47, SIRP-α, and CD200, as well as the mRNA level of IL-4, were downregulated in epileptogenic lesions of FCD IIb and TSC compared with the control specimens, whereas CD200R levels were not significantly changed. CD47, SIRP-α, and CD200 were decreasingly expressed in dysmorphic neuron, balloon cells, and giant cells. CD47 Fc and CD200 Fc could inhibit IL-6 release but did not suppress IL-1β or IL-17 production. Our results suggest that microglial activation may be partially caused by CD47/SIRP-α- and CD200/CD200R-mediated reductions in the immune inhibitory pathways within FCD IIb and TSC cortical lesions where chronic neuroinflammation has been established. Upregulation or activation of CD47/SIRP-α and CD200/CD200R may have therapeutic potential for controlling neuroinflammation in human FCD IIb and TSC.
Epilepsy is an abnormal neurologic disorder distinguished by the recurrent manifestation of seizures, and the precise underlying mechanisms for its development and progression remain uncertain. In recent years, the hypothesis that inflammatory mediators and corresponding pathways contribute to seizures has been supported by experimental results. The potential involvement of neuroinflammation in the development of epilepsy has garnered growing interest. This review centers attention on the involvement of inflammatory mediators in the emergence and progression of epilepsy within recent years, focusing on both clinical research and animal models, to enhance comprehension of the intricate interplay between brain inflammation and epileptogenesis.
Focal cortical dysplasia (FCD) is one of the major causes of refractory epilepsy. Evidence suggests that neuroinflammation contributes to the epileptogenesis of FCD. Downregulation of cluster of differentiation 200 (CD200) leads to neuroinflammation. We previously reported decreased expression of CD200 in brain lesions of FCD patients. In this study, we examined the expression and influences of CD200 on epileptogenesis in a mouse model of FCD. Video monitoring revealed an increased number of motor seizures in cd200 knockout (cd200–/–) FCD mice compared to the wild-type (WT) FCD mice, and CD200 fusion protein (CD200 Fc) downregulated the number of motor seizures in WT FCD mice. Western blotting results displayed a decreased protein expression of CD200 in FCD mice versus the control groups (CTX), and the relative protein level of CD200 is negatively correlated with motor seizure occurrence. Immunohistochemistry and double-labeled immunofluorescence showed that CD200 was expressed in neurons and astrocytes, not in microglia. Correlation analysis revealed a negative correlation between the immunoreactivity (IR) scores of CD200 and the number of ionized calcium binding adaptor molecule 1 (IBA1)-positive microglia. Enzyme-linked immune sorbent assays (ELISAs) showed that the production of interleukin-1β (IL-1β), IL-6, and IL-17 was upregulated in cd200–/– FCD compared to the CTX. In addition, CD200 Fc could downregulate the expression of IL-1β, IL-6, and IL-17, and up-regulate the expression of downstream of tyrosine kinase 2 (Dok2), which is the downstream molecular of the CD200 pathway. Our findings suggest that CD200 may play a pivotal role in the epileptogenesis of FCD.